Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $440.68, moving -0.72% from the previous trading session. This change lagged the S&P 500's daily gain of 0.92%. Meanwhile, the Dow ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...

Piper Sandler lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $533 from $535 and keeps an Overweight rating on the shares ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

These real-time tables help economic and social statistics users to better analyze the impact and development of policy, to prepare forecasts, and to test econometric models ... American Product ...

Mnwabisi Mbangata arrived at Vertex Pharmaceuticals almost two years ago with nearly a decade of experience — including five years at Eli Lilly in various roles — in bringing innovative therapies to ...

Ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) were provided by 23 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise ...

This innovative method combines deep learning with physics-based modeling to predict melt pool behavior faster ... to improve the efficiency of SLM processes, enable intelligent real-time process ...

Before locking in any college football bowl or CFP picks, be sure to see the latest college football predictions from SportsLine's proven model. The model simulates every FBS game 10,000 times.

Mivelsiran sodium is under clinical development by Alnylam Pharmaceuticals and currently in Phase II for Unspecified Central Nervous System Disorders. According to GlobalData, Phase II drugs for ...

A novel computational framework revolutionizes antibody design, offering precise predictions and unlocking insights into the immune system’s ... address challenges in modeling the antibody ...